What is HC Wainwright’s Estimate for TNGX Q1 Earnings?

Tango Therapeutics, Inc. (NASDAQ:TNGX) – Analysts at HC Wainwright issued their Q1 2026 earnings per share estimates for shares of Tango Therapeutics in a research note issued to investors on Monday, April 14th. HC Wainwright analyst R. Burns anticipates that the company will post earnings of ($0.39) per share for the quarter. HC Wainwright currently has a “Buy” rating and a $13.00 target price on the stock. The consensus estimate for Tango Therapeutics’ current full-year earnings is ($1.19) per share. HC Wainwright also issued estimates for Tango Therapeutics’ Q2 2026 earnings at ($0.37) EPS, Q3 2026 earnings at ($0.38) EPS and Q4 2026 earnings at ($0.40) EPS.

Tango Therapeutics Trading Down 6.9 %

Tango Therapeutics stock opened at $1.28 on Tuesday. The company has a market capitalization of $138.38 million, a price-to-earnings ratio of -1.08 and a beta of 1.03. Tango Therapeutics has a 12 month low of $1.11 and a 12 month high of $12.02. The stock’s 50 day moving average is $1.84 and its 200-day moving average is $3.37.

Tango Therapeutics (NASDAQ:TNGX) last posted its earnings results on Thursday, February 27th. The company reported ($0.35) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.32) by ($0.03). Tango Therapeutics had a negative return on equity of 49.64% and a negative net margin of 284.42%. The company had revenue of $4.12 million for the quarter, compared to analyst estimates of $7.84 million.

Institutional Trading of Tango Therapeutics

A number of institutional investors have recently bought and sold shares of the business. Dynamic Technology Lab Private Ltd bought a new position in shares of Tango Therapeutics during the fourth quarter worth approximately $33,000. Stonebrook Private Inc. bought a new position in Tango Therapeutics during the 4th quarter worth $34,000. Ameriprise Financial Inc. acquired a new position in Tango Therapeutics in the 4th quarter valued at $35,000. Sherbrooke Park Advisers LLC bought a new stake in shares of Tango Therapeutics during the 4th quarter valued at $38,000. Finally, Squarepoint Ops LLC acquired a new stake in shares of Tango Therapeutics during the 4th quarter worth $40,000. Institutional investors own 78.99% of the company’s stock.

Insider Buying and Selling at Tango Therapeutics

In related news, CEO Barbara Weber sold 9,778 shares of the company’s stock in a transaction dated Tuesday, February 4th. The shares were sold at an average price of $2.99, for a total value of $29,236.22. Following the transaction, the chief executive officer now directly owns 1,631,264 shares in the company, valued at approximately $4,877,479.36. This represents a 0.60 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Insiders have sold a total of 24,268 shares of company stock valued at $72,561 in the last ninety days. 6.30% of the stock is currently owned by corporate insiders.

About Tango Therapeutics

Tango Therapeutics, Inc, a biotechnology company, discovers and develops drugs for the treatment of cancer. Its lead program is TNG908, a synthetic lethal small molecule inhibitor of protein arginine methyltransferase 5 that is being developed as a treatment for cancers with methylthioadenosine phosphorylase deletions.